
|Articles|August 18, 2012
Biosimilars: Overview of Legislation, Policy, and Current State of Implementation
Advertisement
Enduring Webcast: Biosimilars: Overview of Legislation, Policy and Current State of Implementation
This webcast was brought to you by Amgen.
The faculty for this webcast:
- Defined therapeutic equivalence for small molecule generics
- Described how biologics differ from small molecule drugs
- Explained how the Biologics Price Control and Innovation Act amends the Public Health Service Act and the key requirements of the US biosimilars pathway
- Discussed the difference between biosimilarity and interchangeability
- Reviewed the US legislation for intellectual property and payment provisions
Length of webcast: 14 minutes
System Requirements
PC-based attendees
Required: Windows® 7, Vista, XP, 2003 Server or 2000
Macintosh®-based attendees
Required: Mac OS® X 10.4.11 (Tiger®) or newer
70575-R1-V1
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss
2
Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year
3
GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis
4
Oral Orforglipron Added to Basal Insulin Cuts HbA1c in Type 2 Diabetes
5



